Technical Analysis for CANF - Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Grade	Last Price	% Change	Price Change
	2.44	2.09%	0.05

CANF closed up 2.09 percent on Friday, November 15, 2019, on 9 percent of normal volume.

ADX	Long-Term	Intermediate-Term	Short-Term
Strong	Down	Up	Up
See historical CANF trend table...

Date	Alert Name	Type	% Chg
Nov 14	20 DMA Support	Bullish	2.09%
Nov 14	50 DMA Support	Bullish	2.09%
Nov 13	20 DMA Support	Bullish	2.95%
Nov 13	50 DMA Support	Bullish	2.95%
Nov 13	Narrow Range Bar	Range Contraction	2.95%
Nov 12	Bearish Engulfing	Bearish	0.83%
Nov 12	Outside Day	Range Expansion	0.83%
Nov 11	Narrow Range Bar	Range Contraction	-1.61%
Nov 11	NR7	Range Contraction	-1.61%
Nov 11	NR7-2	Range Contraction	-1.61%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Can-Fite BioPharma, Ltd., a biotechnology company, develops drugs for the treatment of cancer and autoimmune inflammatory diseases. The company principally develops CF101 that is in Phase III study for the treatment of psoriasis; and has completed Phase II study for the treatment of rheumatoid arthritis and glaucoma, as well as completed Phase III study for the treatment of dry eye and Phase I study for the treatment of uveitis. It also develops CF102, which is in Phase II study for the treatment of hepatocellular carcinoma; and CF602 that has completed pre-clinical trial for the treatment of inflammatory diseases. The company was founded in 2000 and is based in Petach Tikva, Israel.
Medicine Biotechnology Cancer Medical Specialties Immunology Treatment Of Cancer Psoriasis Rheumatoid Arthritis Glaucoma Inflammatory Diseases Arthritis Immunosuppressants Hepatocellular Carcinoma Uveitis Biotie Therapies Treatment Of Inflammatory Diseases Treatment Of Psoriasis

Indicator	Bull Case	Neutral / Hold	Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary:	Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

Date	Title
Nov 15	The Week In Cannabis: Stocks Fall On Poor Earnings, More Americans Support Legalization
Nov 11	Can-Fite Obtains Patent For Treatment Of Osteoarthritis In Mammals
Nov 11	Can-Fite Granted U.S. Patent for Piclidenoson in the Treatment of Osteoarthritis, Positioning this Indication for Animal Health Market
Nov 4	NIO, RACE among premarket gainers
Nov 4	Can-Fite Initiates Compassionate Use Program for Namodenoson in the Treatment of Liver Cancer, Enrolls and Treats Patients
Nov 1	ANET, PINS among premarket losers
Oct 31	KHC, SPWR among premarket gainers
Oct 31	Can-Fite up 36% premarket on advancement of Namodenoson
Oct 31	U.S. FDA Agreed with Can-Fite’s Proposed Pivotal Phase III Trial Design to Support a New Drug Application Submission and Approval of Namodenoson in the Treatment of Liver Cancer
Oct 21	BNTX, COTY, INFY, MFGP and SGEN among midday movers

Pivot Point Level	Traditional / Classic	Fibonacci	Demark	Woodie	Camarilla
Resistance 4 (R4)					2.64
Resistance 3 (R3)	2.62	2.53			2.60
Resistance 2 (R2)	2.53	2.48		2.54	2.59
Resistance 1 (R1)	2.49	2.45	2.51	2.51	2.58
Pivot Point	2.40	2.40	2.42	2.41	2.40
Support 1 (S1)	2.36	2.35	2.38	2.38	2.30
Support 2 (S2)	2.27	2.32		2.28	2.29
Support 3 (S3)	2.23	2.27			2.28
Support 4 (S4)					2.25